Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cogent Biosciences ( (COGT) ) has shared an announcement.
At its Annual Meeting, Cogent Biosciences‘ stockholders approved an amendment to the company’s Certificate of Incorporation to provide exculpation from liability for its officers, which was filed and became effective on June 4, 2025. Additionally, all director nominees were elected, and other proposals, including the ratification of the accounting firm PricewaterhouseCoopers LLP and an advisory vote on executive compensation, were approved. The company also plans to present at the Jefferies Global Healthcare Conference on June 5, 2025, highlighting its ongoing clinical and preclinical programs, with significant market opportunities for its product candidates.
The most recent analyst rating on (COGT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cogent Biosciences stock, see the COGT Stock Forecast page.
Spark’s Take on COGT Stock
According to Spark, TipRanks’ AI Analyst, COGT is a Underperform.
Cogent Biosciences is currently facing significant financial difficulties, with no recent revenue, ongoing operating losses, and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is unattractive due to a negative P/E ratio and absence of dividends. These factors contribute to the lowest overall stock score, highlighting substantial risks for investors.
To see Spark’s full report on COGT stock, click here.
More about Cogent Biosciences
Cogent Biosciences operates in the biotechnology industry, focusing on the development of innovative therapies for genetically driven diseases. The company is particularly involved in the research and development of targeted therapies for conditions such as systemic mastocytosis and gastrointestinal stromal tumors, with a strong emphasis on their investigational product candidate, bezuclastinib.
Average Trading Volume: 1,360,809
Technical Sentiment Signal: Sell
Current Market Cap: $659.2M
See more data about COGT stock on TipRanks’ Stock Analysis page.